title: Effects of celecoxib and ibuprofen on metabolic disorders induced by Walker-256 tumor in rats.
abstract: The contribution of anti-inflammatory property of celecoxib in the improvement of metabolic disorders in cancer is unknown. The purpose of this study was to compare the effects of celecoxib and ibuprofen, non-steroidal anti-inflammatory drugs (NSAIDs), on several metabolic changes observed in Walker-256 tumor-bearing rats. The effects of these NSAIDs on the tumor growth were also assessed. Celecoxib or ibuprofen (both at 25 mg/Kg) was administered orally for 12 days, beginning on the day the rats were inoculated with Walker-256 tumor cells. Celecoxib treatment prevented the losses in body mass and mass of retroperitoneal adipose tissue, gastrocnemius, and extensor digitorum longus muscles in tumor-bearing rats. Celecoxib also prevented the rise in blood levels of triacylglycerol, urea, and lactate, the inhibition of peripheral response to insulin and hepatic glycolysis, and tended to attenuate the decrease in the food intake, but had no effect on the reduction of glycemia induced by the tumor. In addition, celecoxib treatment increased the number of Walker-256 cells with signs of apoptosis and the tumor necrosis area and prevented the tumor growth. In contrast, ibuprofen treatment had no effect on metabolic parameters affected by the Walker-256 tumor or tumor growth. It can be concluded that celecoxib, unlike ibuprofen, ameliorated several metabolic changes in rats with Walker-256 tumor due to its anti-tumor effect and not its anti-inflammatory property.
authors.affiliation: Department of Physiological Sciences, State University of Londrina, Londrina, PR, 86051-990, Brazil.
authors.forename: Camila Oliveira
authors.initials: CO
authors.lastname: de Souza
authors.forename: Mirian Ayumi
authors.initials: MA
authors.lastname: Kurauti
authors.forename: Flaviane
authors.initials: F
authors.lastname: de Fatima Silva
authors.forename: Hely
authors.initials: H
authors.lastname: de Morais
authors.forename: Glaucia Regina
authors.initials: GR
authors.lastname: Borba-Murad
authors.forename: Fábio Goulart
authors.initials: FG
authors.lastname: de Andrade
authors.forename: Helenir Medri
authors.initials: HM
authors.lastname: de Souza
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology* / Q000627:therapeutic use; D019540:Area Under Curve; D002100:Cachexia / Q000188:drug therapy* / Q000209:etiology; D002279:Carcinoma 256, Walker / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D000068579:Celecoxib; D045744:Cell Line, Tumor; D004435:Eating / Q000187:drug effects; D007052:Ibuprofen / Q000494:pharmacology* / Q000627:therapeutic use; D050152:Intra-Abdominal Fat / Q000187:drug effects / Q000473:pathology; D008297:Male; D009368:Neoplasm Transplantation; D009929:Organ Size / Q000187:drug effects; D011720:Pyrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D017208:Rats, Wistar; D013449:Sulfonamides / Q000494:pharmacology* / Q000627:therapeutic use; D015431:Weight Loss / Q000187:drug effects
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib; D007052:Ibuprofen